Cellular expression of Mcl-1, an anti-apoptotic Bcl-2 family member, is tightly regulated. Recently, Bcl-2 expression was shown to be regulated by microRNAs, small endogenous RNA molecules that regulate protein expression through sequence-specific interaction with messenger RNA. By analogy, we reasoned that Mcl-1 expression may also be regulated by microRNAs. We chose human immortalized, but non-malignant, H69 cholangiocyte and malignant KMCH cholangiocarcinoma cell lines for these studies, because Mcl-1 is dysregulated in cells with the malignant phenotype. By in silico analysis, we identified a putative target site in the Mcl-1 mRNA for the mir-29 family, and found that mir-29b was highly expressed in cholangiocytes. Interestingly, mir-29b was downregulated in malignant cells, consistent with Mcl-1 protein upregulation. Enforced mir-29b expression reduced Mcl-1 protein expression in KMCH cells. This effect was direct, as mir-29b negatively regulated the expression of an Mcl-1 3 0 untranslated region (UTR)-based reporter construct. Enforced mir-29b expression reduced Mcl-1 cellular protein levels and sensitized the cancer cells to tumor necrosis factor-related apoptosisinducing ligand (TRAIL) cytotoxicity. Transfection of non-malignant cells (that express high levels of mir-29) with a locked-nucleic acid antagonist of mir-29b increased Mcl-1 levels and reduced TRAIL-mediated apoptosis. Thus mir-29 is an endogenous regulator of Mcl-1 protein expression, and thereby, apoptosis.
Introduction
Mcl-1 is a potent multidomain anti-apoptotic protein of the Bcl-2 family containing Bcl-2-homology domains BH1-3 that heterodimerizes with Bcl-2 family members. Specifically, Mcl-1 binds to the BH3-only proteins Bim, Bid, Bik, Noxa and Puma (Chen et al., 2005) , as well as Bak (Cuconati et al., 2003) . Binding to Bid and Bim protects against tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced cell death. Either depletion of Mcl-1 (Nijhawan et al., 2003) or disruption of the interaction between Mcl-1 and Bak coincides with apoptosis following a cytotoxic stimulus (Leu et al., 2004) . Still, the mechanism by which Bcl-2 family members modulate apoptosis remains incompletely understood (Willis and Adams, 2005) .
Tight regulation of Mcl-1 protein levels is necessary; on one hand, insufficient Mcl-1 can result in inappropriate cell death and on the other hand, overexpression poses a risk of cellular transformation. For example, conditional deletion of Mcl-1 results in bone marrow failure owing to inappropriate apoptosis of precursor cells (Opferman et al., 2003) , whereas transgenic mice with constitutive Mcl-1 expression develop hematologic malignancies (Zhou et al., 2001) . Mcl-1 overexpression is commonly observed in cancers (Konopleva et al., 2006) including cholangiocarcinoma (Kobayashi et al., 2005) , and overexpression correlates with cancer prognosis and recurrence (Kaufmann et al., 1998; Wuilleme-Toumi et al., 2005) . In cholangiocarcinoma, overexpression of Mcl-1 causes resistance to TRAIL-induced apoptosis, whereas suppression sensitizes cells to apoptosis (Taniai et al., 2004) .
The regulation of Mcl-1 protein levels is complex. Transcriptionally, Mcl-1 mRNA is upregulated by cytokines IL-3, IL-5, IL-6, IL-15, IL-22 and IFN-a, as well as by granulocyte monocyte colony stimulating factor (GM-CSF) and epidermal growth factor receptor (EGFR) activation (reviewed by Michels et al., 2005) . At the protein level, the half-life of Mcl-1 is approximately 2-4 h. Ubiquitination by the E3-ligase Mule leads to rapid degradation by the proteasome, and prevention of ubiquitination increases Mcl-1 levels and enhances protection (Zhong et al., 2005) . Alternatively, bile acids prevent Mcl-1 turnover through an EGFRdependent pathway, again enhancing protection (Yoon et al., 2002) . Thus Mcl-1 is regulated by multiple cellular processes.
Given the complexities of Mcl-1 regulation, it is highly likely that other mechanisms exist. Recent work has described a potential new mechanism for protein regulation, namely through microRNAs (Bartel, 2004) . MicroRNAs act as endogenous sequence-specific suppressors of translation, and thus can decrease target protein expression (Lewis et al., 2005) . The microRNA-target interaction occurs through base pairing of the 'seed region' of the microRNA (nucleotides 2-7) to the cognate target (Lewis et al., 2005) . Whereas relatively few microRNA targets have been experimentally described, significantly, the prototypical anti-apoptotic protein Bcl-2 is a target of microRNA regulation. mir-15 and mir-16 have base complementarity (including the seed region) to the Bcl-2 mRNA, and overexpression of mir-15/16 leads to decreased Bcl-2 protein and increased cell death . Although microRNAs potentially regulate the expression of other Bcl-2 family proteins, this mechanism of Mcl-1 regulation has not been explored. The objective of the current study was to examine the role of microRNAs in regulation of Mcl-1 expression.
Results
Mcl-1 is a potential target of mir-29 microRNA regulation Predicted Mcl-1-binding microRNAs were located by computer search (Supplementary material) and include . Given the overexpression of Mcl-1 in malignant cholangiocarcinoma cells, we postulated that Mcl-1-inhibitory microRNA would be reduced in these cells, but more abundantly expressed in the H69 nonmalignant cholangiocyte cells, which minimally express Mcl-1. Therefore, Northern blot analysis was performed for microRNAs in H69 cells. Only mir-29 was abundantly expressed in the mature form in H69 cholangiocytes (Figure 1b) , although real-time reverse transcription-polymerase chain reaction (RT-PCR) differed from Northern blot analysis, and signal was detected for all but mir-153 (Supplementary material). Note that the precursor form was detected for all examined microRNAs. Several possible mechanisms could explain this regulation, including regulation of expression through the maturation or nuclear export process (Lee et al., 2002) , or potentially through degradation of the mature microRNA. There is perfect complementarity between mir-29b and the 3 0 untranslated region (UTR) of Mcl-1 over the first nine nucleotides (including the 2-7 seed), consistent with a bona fide mir-29-binding site (Supplementary Table 1 Likely, the mir-29b product (23 nucleotides) predominates in this cell type. Further evidence that mir-29b is detectible with the mir-29a probe is the observation that transfection with pre-mir-29b results in an increased signal on Northern blot analysis using the mir-29a probe ( Figure 3b ). Consistent with the Northern blot analysis, the real-time RT-PCR assay demonstrates the downregulation of mir-29b in KMCH cells (Figure 2c ). In a subset (one-third) of cryopreserved human cholangiocarcinoma specimens (n ¼ 6), mir-29b was downregulated approximately sevenfold by real-time RT-PCR. Thus, mir-29b can be downregulated in human cholangiocarcinoma cells and tissue. (Figure 3d ). The reduction in Mcl-1 protein was specific as protein levels of Bax, Bak, Bcl-X L and Bcl-2 were not altered.
To avoid the cellular stress of the transient transfection process, we also generated two KMCH cell lines stably transfected with mir-29b (K-mir-29-6 and K-mir-29-19). Northern blot analysis confirmed the overexpression of mir-29b compared with the parental KMCH cells (Figure 3e ). Consistent with our other data, and with a role for mir-29b in regulating Mcl-1, these mir-29b overexpressing cells also manifest reduced steady-state levels of Mcl-1 protein (Figure 3f mir-29b acts directly at the Mcl-1 3 0 UTR To demonstrate that the negative effect of mir-29b on Mcl-1 expression was direct, we used a luciferase reporter assay. The alignment of mir-29b with the 3 0 UTR insert is illustrated (Figure 4a ). Cotransfection of HeLa cells with the parental luciferase construct (without the Mcl-1 3 0 UTR) plus the mir-29b expression vector does not significantly change the expression of the reporter (Figure 4b ). However, when the mir-29 target site from the Mcl-1 3 0 UTR is inserted into the luciferase construct, expression of luciferase is strongly decreased when cotransfected with mir-29b (Figure 4b ). This suppression is relieved by a single base mutation in the binding site (Figure 4b ). These data were replicated in KMCH cells (not shown), again the only effect was when both mir-29b and its target sequence were present. Thus, mir-29 directly inhibits the expression of Mcl-1 by binding to its target sequence.
mir-29b sensitizes cells to apoptosis KMCH cholangiocarcinoma cells are resistant to TRAIL-induced cell death compared with their nonmalignant counterpart H69 cells owing to Mcl-1 expression (Taniai et al., 2004) . Therefore, we postulated that transfection of KMCH with mir-29b, which downregulates cellular Mcl-1 levels, would sensitize the cells to TRAIL cytotoxicity. Indeed, transfection with 50 nM precursor mir-29b RNA sensitized KMCH cells to TRAIL-induced apoptosis ( Figure 5 ). Enhanced apoptosis, as assessed by morphology (Figure 5a ) or caspase 3/7 activity (Figure 5b ) was observed in TRAILtreated cells following mir-29b transfection. These data suggest that mir-29b downregulation of Mcl-1 is functional as it sensitizes cells to apoptosis. If this concept is correct, then inhibition of mir-29b should increase Mcl-1 expression and increase cellular resistance to apoptosis.
To test this postulate, H69 cells were employed as they abundantly express mir-29 with a corresponding relative reduction of cellular Mcl-1 protein levels. mir29b function was inhibited by transfecting cells with a locked nucleic acid (LNA) oligonucleotide that binds tightly to mir-29b. Transfection with a mir-29b-targeting LNA increases Mcl-1 cellular protein levels (Figure 6a ). The increased cellular Mcl-1 levels owing to antagonism of mir-29b by LNA protected the H69 cells from TRAIL cytotoxicity (Figure 6b ). Because KMCH cells only weakly express mir-29b, antagonism of mir-29b by LNA transfection in these cells was similar to control, and did not further alter Mcl-1 overexpression (Figure 6a ), nor suppress TRAIL cytotoxicity (Figure 6b) . Consistent with the morphologic assessment of cell death, LNA transfection protected H69 cells from caspase 3/7 activation upon TRAIL treatment (Figure 6c ). KMCH cells were already (McManus, 2003) . Our data extend these concepts by suggesting that decreased mir-29b expression also helps cells evade cell death, a cardinal feature of cancer cells. The decreased expression of mir-29b with concomitant enhancement of Mcl-1 expression may explain in part the upregulation of Mcl-1 in this cancer. Indeed, a convincing precedent for microRNA regulation of Bcl-2 proteins has been established . Our limited data demonstrating a downregulation of mir-29b in a subset of human cholangiocarcinomas also support this concept.
mir-29 may have a broader role in tumor biology in addition to a potential role in cholangiocarcinoma suggested in the current study. For example, mir-29 is also downregulated in aggressive chronic lymphocytic leukemia, colon and breast cancer Cummins et al., 2006; Yanaihara et al., 2006) . mir-29a and mir-29b1 are expressed on the same transcript from a locus at chromosome 7q32 which coincides with the common fragile site FRA7H, and may allow for frequent mir-29 downregulation in these cancers (Calin et al., 2004) . Loss of heterozygosity at this site is associated with more aggressive prostate cancer (Neville et al., 2002) . Iorio et al. (2005) found that mir-29 was downregulated in aggressive breast cancer specimens, those that lacked estrogen and progestin receptors (mir29b) and those with vascular invasion. The relationship between loss of mir-29b expression in human cancer and regulation of target proteins such as Mcl-1 merits further examination.
In summary, Mcl-1 protein expression can be regulated by mir-29b. These studies extend our knowledge of Mcl-1 expression, a key anti-apoptotic protein which has been referred to as a 'linchpin in the network of anti-apoptotic regulators ' (van Delft and Huang, 2006) . Thus, in addition to transcriptional and posttranscriptional regulation, Mcl-1 is also regulated at the translational level by microRNA, an emerging paradigm for many proteins (Bartel, 2004) . Based on these concepts, we propose that the regulation of mir-29b may be a key process in Mcl-1 biology and pathobiology. In particular, mechanisms to enhance mir-29b expression which would reduce cellular Mcl-1 levels could potentially be of value in cancer therapy.
Materials and methods
The methods for cell lines and human tissue, mir-29 binding site sequencing, transient transfection, microRNA array, fluorescent microRNA transfection, Northern blot conditions, reporter gene assay and western blot antibodies are available as Supplementary materials.
MicroRNA target predictions
Computer-based programs were used to predict microRNAs that potentially bind Mcl-1. Using 'MCL1' as a search term, 
Northern blotting
Total RNA isolation was performed as per the manufacturer's instructions, and for some experiments, small RNA species were enriched (mirVana kit, Ambion, Austin, TX, USA). For Northern blotting, the fraction enriched for small RNAs (1 mg per well) or total RNA (5 mg) was run on a 15% polyacrylamide-urea gel, transferred to a Zeta-probe membrane (BioRad, Hercules, CA, USA) and UV-crosslinked.
Real-time reverse transcription polymerase chain reaction Real-time RT-PCR for human Mcl-1 was performed as described (Yoon et al., 2002) using a capillary thermocycler (Lightcycler, Roche, Mannheim, Germany) . For microRNA RT-PCR, the dominant family member was determined by the microRNA array (below) and mir-29b, -125b, -153, -193b and -320 were detected (Applied Biosystems, Foster City, CA, USA). As a control, the small housekeeping RNA Z30 was amplified and quantitated. RT-PCR was performed on 50 ng total RNA. The mir-29b reaction was tested on 0.01-100 ng of target RNA (H69 cells) and the plot of cycle number versus log RNA concentration was linear over this range. The PCR products for mir-29b, -125b, -153, -193b and -320 were cloned (pCR2.1 TOPO, Invitrogen, Carlsbad, CA, USA) and sequenced to confirm the product identity. Products for mir-29b and Z30 were gel purified (single visible band) and quantitated by absorbance at 260 nm to generate a standard curve (linear at least between 10 3 and 10 9 copies).
RNA transfection
In vitro transcribed RNA (MegaScript; Ambion, Austin, TX, USA) was generated corresponding to approximately the precursor stem-loop of mir-29b-1. This was synthesized using a gel-purified PCR-generated amplicon containing the precursor for mir-29b-1 using genomic DNA as template (forward primer 5 0 -GGTACCGGTTGTCTTGGGTTTATTG; reverse 5 0 -GAATTCAAATACTTCAGAGCTG). The T7 promoter was added at the 5 0 end of the forward primer by a second PCR. Control RNA (antisense to the pre-mir-29 sequence) was generated from the same amplicon except that the T7 Antagonism of mir-29b was through transfection of a chimeric LNA/DNA oligonucleotide designed to hybridize to mir-29. The sequence used was 5 0 -AACACT *G*A*T*T TCAATGGT *G*C*T*A (Proligo, Boulder, CO, USA) where * before a base denotes an LNA base (2 0 O-4 0 C-methylene modified).
Luciferase assay
The p-MIR-report plasmid (Ambion, Austin, TX, USA) was modified by insertion of the Mcl-1-derived mir-29b binding site or a single-base mutant thereof into the 3 0 UTR. These reporters were transfected into HeLa or KMCH cells, and transfection efficiency corrected by a renilla luciferase vector (pRL-CMV, Promega, Madison, WI, USA). The p29b expression plasmid was co-transfected where indicated. HeLa cells were chosen, because they are readily transfected, and they express low levels of endogenous mir-29 (Lagos-Quintana et al., 2001) . Comparable results were observed in KMCH cells.
Western blotting
Proteins were resolved on 12% polyacrylamide gels, transferred to nitrocellulose membrane (Biorad, Hercules, CA, USA) and blocked with 5% nonfat dairy milk in Tris-buffered saline (20 mM Tris, 150 mM NaCl, pH 7.4) with 0.1% Tween-20.
Immunofluorescence Phosphate-buffered saline (PBS; 0.9%, sodium chloride, 20 mM sodium phosphate, pH 7.4) was used for all wash steps (three times 5 min each). Cells grown on glass coverslips were washed, and then fixed with paraformaldehyde (3% paraformaldehyde in 100 mM PIPES, pH 6.95, 1 mM EGTA, 3 mM magnesium sulfate). Cells were washed of fixative and permeabilized with 0.0125% 3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonic acid (CHAPS; in PBS). Nonspecific protein binding was blocked with 5% normal goat serum (Sigma, St Louis, MO, USA) and 5% glycerol in PBS.
Mcl-1 was detected using a monoclonal antibody (1:250 dilution in blocking buffer, Epitomics, Burlingame, CA, USA), washed and detected with Texas-red conjugated secondary antibody (Molecular Probes, Eugene, OR, USA). Finally, cells were washed with PBS, then rinsed with water and mounted onto slides using ProLong Antifade Kit (Molecular Probes). Images were captured by confocal microscopy using a Zeiss LSM 510 inverted microscope (Carl Zeiss Inc., Thornwood, NJ, USA).
Cell death assays Cells plated at least 1 day prior were transfected with pre-mir29b and incubated for 22 h. TRAIL (R&D Systems, Minneapolis, MN, USA) was then added (2 ng/ml final) in fresh media and the cells were treated for 4 h. Cells were stained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI, 1000X stock ¼ 5 mg/ml in water; Sigma) and observed under fluorescence microscopy. Apoptosis was quantitated by counting nuclei with characteristic apoptotic changes. Media was changed for untreated cells whereas, at the same time, TRAIL was added to treated cells to keep conditions the same. Caspase 3/7-like activity (DEVDase activity) was measured using the ApoOne Kit (Promega).
Statistical analysis
Data are expressed as mean7s.e.m., all blots represent at least three separate experiments. Cell death data shown were done in triplicate for each experiment, and are representative of three or more experiments. Comparison of the expression of mir-29b using RT-PCR was made using the Student's t-test, for all other analyses, multiple comparisons were possible so ANOVA was used with Bonferroni post hoc correction.
